Boston, MA 07/23/2013 (wallstreetpr) – More recently, Infinity Pharmaceutical Inc (NASDAQ:INFI) has reported the results from an ongoing phase 1 study of the drug IPI-145. Per the president of research and development, from the early results of phase 1 study of IPI-145 which were exciting, the IPI-145 is believed to have the potential to become the best in class PI3K inhibitor for this indication. Following this positive results from the ongoing phase 1 study, Infinity Pharmaceuticals has moved forward in evaluating dosing of IPI-145 at 25 mg twice per day in the patients with refractory iNHL in the phase 2 studies. This is because in the phase 1 study, 25 mg has shown to have a robust clinical activity. This has demonstrated the inhibition of PI3K gamma to the minimum of 50% in addition to the complete inhibition of PI3K delta.
The company’s market capitalization value is about 952.27 million. Infinity Pharmaceutical Inc has a value of about 77% for the institutional investors share. In the trading session during the early weeks of this month, the stock of Infinity Pharmaceuticals was -1.28% down on the total number of 192,120 shares being traded. This was following the announcement of Infinity Pharmaceuticals to present at the JMP Securities Healthcare Conference of this year. The stock of the company was -67.85% down from the 52-week higher. This prompted the Growing Stock Report to include the company’s stock to their NASDAQ Decliners Watch List. But, after their participation in JMP Securities Healthcare Conference, the stock of Infinity Pharmaceuticals closed higher.
Following this, the stock of the company continued to increase which was followed by the announcement that the management of James Flynn’s Deerfield has disclosed the ownership for 2.3 million shares. In other reports, it has been stated that the Infinity Pharmaceutical shares have been oversold so severely which made the upside potential of the company even more.
